The $10.50 figure is not a published official consensus; it is the average of four current, attributable price targets collected from individual analyst reports. CRNC targets used include Craig-Hallum at $10.00 (Hold, August 2026), Goldman Sachs at $9.00 (Neutral, raised from $8.00 in May 2026), Cantor Fitzgerald at $11.00 (Overweight, initiated April 2026), and TD Cowen at $12.00 (Hold, February 2026). The range is narrow for a small-cap turnaround story, spanning $9.00 to $12.00, and the average lands at $10.50.
The overall tone is cautious optimism. Cantor Fitzgerald's Overweight initiation points to the generative-AI opportunity and improving cash generation, while Hold ratings from Goldman Sachs and TD Cowen reflect concern about limited near-term visibility into auto volumes and the pace of the xUI ramp. The clustering of targets just above and below $10.50 signals that analysts see meaningful upside but not a high-conviction re-rating. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Cerence shares last traded around $6.98, near the lower end of a 52-week range of $5.85 to $13.28, with a market capitalization of about $316 million. Reaching $10.50 implies a move of approximately 50%, which qualifies as a substantial advance rather than an incremental one.
The path would likely depend on sustained execution rather than a single catalyst. Cerence's fiscal 2026 (ending September 30, 2026) guidance was raised to revenue of $305 million to $320 million, adjusted EBITDA of $60 million to $70 million, and free cash flow of $66 million to $76 million. A $49.5 million Samsung patent-licensing payment boosted earlier results, but management has emphasized high-single-digit growth in core technology revenue. A move toward $10.50 would probably require investors to reward accelerating core growth, expanding xUI design wins, and de-leveraging, rather than one-time licensing gains.
Several factors underpin the bullish case. Cerence holds roughly 50% of worldwide auto production using its technology and reports a five-year backlog near $970 million. The xUI platform, built around large language models (LLMs), is ramping with multiple original-equipment-manufacturer programs, and management has pointed to higher per-vehicle pricing. Cost discipline has pushed the company to positive adjusted EBITDA and record free cash flow. Patent and IP monetization, illustrated by the Samsung cross-license, provides a recurring source of non-core income, while partnerships with technology leaders broaden the addressable market beyond automotive.
The risks are equally tangible. Cerence's revenue is tied to global auto production, which has been uneven, and its core growth remains single-digit. It competes against well-capitalized platforms from Amazon, Apple, and Google, as well as pure-play rivals such as SoundHound AI (SOUN). The balance sheet remains a concern, with roughly $90 million of debt coming due in the near term. Analysts and commentators also caution that the stock's valuation could compress if the shift to recurring, subscription-based revenue disappoints or if the AI narrative cools. Technical resistance and a volatile, low-price stock can amplify drawdowns.
The 52-week range of $5.85 to $13.28 frames the current setup. The stock sits well below its prior high, meaning the $10.50 target sits roughly midway through that range. The $9.00 area, marked by Goldman Sachs' target and recent trading activity, is a logical near-term hurdle, while the $12.00-to-$13.00 zone represents the next major resistance from the earlier 2026 peak. A sustained move above $9.00 could establish higher support and open a path toward the target, whereas failure to hold above the low-$6.00 area would keep the stock range-bound.
Analyst price targets typically reflect a roughly 12-month research horizon, though individual firms vary. For Cerence, the next earnings report is scheduled for early December 2026, making quarterly results and fiscal 2027 guidance the most important near-term inputs. Investors should track xUI design wins and production launches, core (ex-licensing) revenue growth, free cash flow, debt reduction, auto-production data, and any additional patent-licensing settlements. Changes to analyst targets following earnings will also signal whether the $10.50 anchor remains intact. From what I see, the upcoming earnings will be a key checkpoint.
The $10.50 target is best understood as the midpoint of four credible analyst views spanning $9.00 to $12.00, rather than a precise forecast. At a last price near $6.98, reaching that level requires a substantial gain of about 50%. The case rests on xUI adoption, raised profitability guidance, IP monetization, and Cerence's entrenched position in automotive voice AI. The counterarguments are auto-production sensitivity, formidable competition, a still-leveraged balance sheet, and the burden of proving sustainable subscription growth. With earnings approaching and targets clustered tightly, the question of whether CRNC can reach $10.50 will hinge on execution over the next several quarters rather than on any single announcement.
I find Tickeron’s AI Daily Buy/Sell Signals useful when monitoring names like Cerence. The tool applies artificial intelligence to scan thousands of stocks and ETFs, producing Buy, Sell, or Hold signals based on technical behavior and market shifts. It adds a layer of perspective alongside fundamental analysis, especially for volatile stocks where timing matters. In my view, combining it with earnings tracking and design-win updates helps keep the overall picture in focus without replacing deeper research.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where CRNC declined for three days, in 302 of 343 cases, the price declined further within the following month. The odds of a continued downward trend are 88%.
The Momentum Indicator moved below the 0 level on November 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CRNC as a result. In 74 of 85 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 87%.
The Moving Average Convergence Divergence Histogram (MACD) for CRNC turned negative on November 12, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In 42 of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at 84%.
CRNC moved below its 50-day moving average on November 12, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for CRNC crossed bearishly below the 50-day moving average on November 16, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 62%.
The Aroon Indicator for CRNC entered a downward trend on November 19, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +7.47% 3-day Advance, the price is estimated to grow further. Considering data from situations where CRNC advanced for three days, in 199 of 258 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
CRNC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Valuation Rating of 13 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.216) is normal, around the industry mean (-1.939). P/E Ratio (-22.639) is within average values for comparable stocks, (9.673). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.843). Dividend Yield (0.000) settles around the average of (0.072) among similar stocks. P/S Ratio (1.132) is also within normal values, averaging (71.334).
The Tickeron Price Growth Rating for this company is 75 (best 1 - 100 worst), indicating slightly worse than average price growth. CRNC’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 93 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CRNC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a company, which builds automotive cognitive assistance solutions to power natural and intuitive interactions between automobiles, drivers and passengers, and the broader digital world
Industry PackagedSoftware